0009K0.KQ Aimed Bio

Healthcare Biotechnology KOSDAQ
18,860 KRW
Close of Oct 30, 2026
17,400 80,200
Market cap
KRW 1.21T
P/E
33.0x
P/B
5.92x
ROE
8.7%
Dividend yield
-
Fundamental score
0.9/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0009K0.KQ undervalued?

Graham number
Price18,860
Graham value6,402
Premium194.6%

0009K0.KQ trades 194.6% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aimed Bio fundamental analysis

5 of 22 checks passed

ROE 0/2

Low return on equity (8.7%), below 10%.

ROA 1/1

Return on assets (8.4%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (252.0%) is above the industry median (4.8%).

Revenue Growth 0/2

Revenue did not grow over the past 3 years or is not reported.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Debt is not reported.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 0/1

PE (33.0x) is above the market median (11.3x).

PE vs Industry 0/1

PE (33.0x) is above the industry median (28.9x).

PBV 0/1

Price to book (5.9x) is above the industry median (2.4x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 195.3, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Aimed Bio stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aimed Bio

Aimed Bio Inc. develops therapeutic solutions for patients with brain diseases, including neuro-oncological and degenerative diseases. Its multidisciplinary platform offers antibody-drug conjugates, blood-brain barrier penetration, brain immune modulation, and patient-derived models (PDC/PDX). Aimed Bio Inc. was founded in 2018 and is based in Seoul, South Korea.

Full company profile